netFormulary The Pennine Acute Hospitals NHS
NHS Trust Formulary  
 Introduction
Pennine Acute Hospitals NHS Trust Formulary

Useful Links

Medicines Information Enquiry Form GMMMG Website National Institute for Health and Care Excellence Website
Report an Adverse Drug Reaction to the MHRA NICE Clinical Knowledge Summaries NHS Choices
PAT New Product Application Form Injectable Medicines Guide BNF

News Feed

New first line insulin glargine June 2016 Abasaglar
New addition to the formulary June 2016 Edoxaban (oral anticoagulant)
New addition to the formulary May 2016 Tapentadol (Palexia SR)
Stalevo now formulary Dopamine receptor agonists
Changes to COPD inhaler formulary Jan 2016 Chapter 03.01
New addition to the formulary Dec 2015 Ferinject (ferric carboxymaltose)

>>> more news

Welcome to the Pennine Acute Hospitals NHS Trust Formulary

This Formulary is intended for use by staff working within Pennine Acute Hospitals NHS Trust, but is fully accessible to the public via www.formulary.pat.nhs.uk.

The Formulary is underpinned by the Greater Manchester Medicines Management Group (GMMMG) Joint Formulary which was produced in consultation with primary and secondary care prescribers within the Greater Manchester Health Community, to support safe, evidence-based and cost-effective prescribing to improve patient care.  Use of the joint formulary helps to ensure seamless prescribing between hospital prescribers and GPs thereby reducing the confusion that can sometimes happen if medicines are changed. 

The therapeutic sections of the Formulary are based on the chapters of the British National Formulary (BNF) for ease of cross-reference. Where appropriate, the Formulary also links users to any relevant national guidelines (eg: NICE) or product information (eg: electronic Medicines Compendium). All prescribers should continue to refer to the current BNF for information on indications, dosage, side-effects, drug interactions and more comprehensive information on a wider range of medicines.

Where there is a clear first or second line choice for a group of medicines, this is displayed. Otherwise, Formulary-approved medicines appear in no particular order. Any medicines with restrictions on use are marked with Restricted Item.

Where a medicine appears on the GMMMG RAG list, they are marked with the relevant traffic light symbol.

The Pennine Acute Formulary website is a work-in-progress. You will note that some BNF chapters are missing; these are currently under construction. The Pennine Acute Drugs and Therapeutics Committees welcome any feedback on the current content. This can be sent easily, using the feedback tab.



Requesting an Item to be Added to the Formulary

An application must be submitted to the relevant Divisional Drug and Therapeutics Committee and must be supported by the relevant Clinical Director.

An application must be submitted when any of the following is required:

(a)    Introduction of a medicinal product which has not previously been used within the Trust, or,

(b)    Use of a medicinal product that has previously been restricted to certain clinicians,
or,

(c)    A change in use or planned increase in use of a medicinal product which is already available, either as a Formulary item or as a restricted item.

It is expected that all requests for the introduction of a medicinal product which has not previously been used within the Trust will comply with the GMMMG Formulary. If the item does not appear either on the GMMMG Formulary or the GMMMG Do Not Prescribe List then it is also expected that a dual submission will be made to the GMMMG Formulary Subgroup using the appropriate application form (follow link).


Cases of Urgent Clinical Need

It is recognised that the formulary will not cover every eventuality or speciality, and there will be instances where prescribing outside of the Formulary will be both necessary and appropriate. In such cases, where there is an urgent clinical need for a non-formulary medicine,the consultant taking care of the patient must speak personally to the Chair of their Divisional Drug and Therapeutics Committee (or in their absence the Deputy Medical Director or Medical Director) to seek approval for the use of the drug on clinical grounds. Once approval is granted, the clinician must speak to the Divisional Management team to determine funding sources. The Director who authorises funding will contact the Pharmacy lead for the relevant Drugs and Therapeutics committee, who will instruct pharmacy departments about stocking the medicine. Stock will not be obtained and/or dispensed by a Pharmacy Department until confirmation of approval from the Divisional Management team has been obtained. The relevant Pharmacy Department can be contacted for advice.

 


 


NetFormulary
   Visits = 42167
   Last updated: 13/09/2016 16:50:45